Abstract:SARS-CoV-2 uses ACE2 to enter target cellsSARS-CoV-2 and SARS-CoV bind with similar affinities to ACE2Structures of SARS-CoV-2 spike glycoprotein in two conformationsSARS-CoV polyclonal antibodies inhibit SARS-CoV-2 spike-mediated entry into cellsThe emergence of SARS-CoV-2 has resulted in >90,000 infections and >3,000 deaths. Coronavirus spike (S) glycoproteins promote entry into cells and are the main target of antibodies. We show that SARS-CoV-2 S uses ACE2 to enter cells and that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to human ACE2, correlating with the efficient spread of SARS-CoV-2 among humans. We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S1/S2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and SARS-related CoVs. We determined cryo-EM structures of the SARS-CoV-2 S ectodomain trimer, providing a blueprint for the design of vaccines and inhibitors of viral entry. Finally, we demonstrate that SARS-CoV S murine polyclonal antibodies potently inhibited SARS-CoV-2 S mediated entry into cells, indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination.<ol class="links-for-figure"><li><a class="anchor download-link u-font-sans" href="https://ars.els-cdn.com/content/image/1-s2.0-S0092867420302622-fx1_lrg.jpg">Download : Download high-res image (222KB)</a></li><li><a class="anchor download-link u-font-sans" href="https://ars.els-cdn.com/content/image/1-s2.0-S0092867420302622-fx1.jpg">Download : Download full-size image</a></li></ol>

SARS-CoV-2 Spike N-Terminal Domain Engages 9- O -Acetylated α2-8-Linked Sialic Acids

Two Receptor Binding Strategy of SARS-CoV-2 Is Mediated by Both the N-Terminal and Receptor-Binding Spike Domain

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Featuring ACE2 binding SARS-CoV and SARS-CoV-2 through a conserved evolutionary pattern of amino acid residues

Identification of Potential Binding Sites of Sialic Acids on the RBD Domain of SARS-CoV-2 Spike Protein

Inter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry

The Effect of Select SARS-CoV-2 N-Linked Glycan and Variant of Concern Spike Protein Mutations on C-Type Lectin-Receptor-Mediated Infection

Single-molecule imaging reveals allosteric stimulation of SARS-CoV-2 spike receptor binding domain by host sialic acid

Spike Glycoprotein-Mediated Entry of SARS Coronaviruses

Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor

N‐glycosylation of the SARS‐CoV‐2 spike protein at Asn331 and Asn343 is involved in spike‐ACE2 binding, virus entry, and regulation of IL‐6

SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2

Prion-like Domains in Spike Protein of SARS-CoV-2 Differ across Its Variants and Enable Changes in Affinity to ACE2

SARS-CoV-2 spike engagement of ACE2 primes S2′ site cleavage and fusion initiation

The accomplices: Heparan sulfates and N-glycans foster SARS-CoV-2 spike:ACE2 receptor binding and virus priming

Exploring the Regulatory Function of the N-terminal Domain of SARS-CoV-2 Spike Protein Through Molecular Dynamics Simulation

Adaptive Evolution of the Spike Protein in Coronaviruses

Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

SARS-CoV-2 S protein:ACE2 interaction reveals novel allosteric targets

The Spike Glycoprotein of Highly Pathogenic Human Coronaviruses: Structural Insights for Understanding Infection, Evolution and Inhibition.